REGULAR CONTENT
Final ID
505
Type
Original Scientific Research-Oral or Pos
Authors
J Fergus1, M Chehab1, J Ciacci1, J Handel1, S Vartanian1, J Campbell1, M Savin1
Institutions
1Oakland University William Beaumont School of Medicine, Royal Oak, MI
Purpose
Considering there are multiple predisposing factors for hepatocellular carcinoma (HCC) that have an impact on disease course, it is important to define survival among patients with HCC of different origins. The purpose of this study is to assess survival of patients undergoing radioembolization for HCC using Yttrium-90 (Y90) microspheres and determine if there are differences in survival for different underlying cause of HCC.
Materials & Methods
A single-center retrospective review of all HCC patients who underwent Y90 radioembolization over an 11-year period was performed. Patient age, gender, underlying HCC diagnosis, date of first treatment with Y90 microspheres, and date of patient death using the United States Social Security Death Index from 1935-2014 were compiled. Overall survival was calculated from the date of first treatment with Y90 microspheres. Kaplan-Meier survival curves and analysis (log-rank test) were used to assess differences in survival among our sample based on the underlying cause of HCC.
Results
105 patients with HCC (76 males, 29 females, median age: 71 years, range: 33-93 years) were included. The underlying liver disease included hepatitis B (n=6; 5.7%), hepatitis C (n=28; 26.7%), alcoholic cirrhosis (n=17; 16.2%), hemochromatosis (n=4; 3.8%), cryptogenic cirrhosis (n=38; 36.2%), and multiple etiologies including hepatitis B, hepatitis C, and/or alcohol cirrhosis (n=12; 11.4%). Median overall survival was 330 days (range: 2-1287 days): hepatitis B, 317 days; hepatitis C, 172 days; alcoholic cirrhosis, 240 days; hemochromatosis, 219 days; cryptogenic cirrhosis, 325 days; or cirrhosis of multiple etiologies, 224 days. The survival distributions did not vary significantly by underlying HCC diagnosis based on the log-rank test (p=0.150). Of the patients with cryptogenic cirrhosis, 84.2% (n=32) had ≥1 risk factor for nonalcoholic fatty liver disease.
Conclusions
In this single-center retrospective review, overall survival of HCC patients treated with Y90 microspheres does not significantly differ by underlying HCC etiology. Further study is needed to determine if the differences observed, such as longer survival for hepatitis B relative to hepatitis C, trend towards significance.
Final ID
505
Type
Original Scientific Research-Oral or Pos
Authors
J Fergus1, M Chehab1, J Ciacci1, J Handel1, S Vartanian1, J Campbell1, M Savin1
Institutions
1Oakland University William Beaumont School of Medicine, Royal Oak, MI
Purpose
Considering there are multiple predisposing factors for hepatocellular carcinoma (HCC) that have an impact on disease course, it is important to define survival among patients with HCC of different origins. The purpose of this study is to assess survival of patients undergoing radioembolization for HCC using Yttrium-90 (Y90) microspheres and determine if there are differences in survival for different underlying cause of HCC.
Materials & Methods
A single-center retrospective review of all HCC patients who underwent Y90 radioembolization over an 11-year period was performed. Patient age, gender, underlying HCC diagnosis, date of first treatment with Y90 microspheres, and date of patient death using the United States Social Security Death Index from 1935-2014 were compiled. Overall survival was calculated from the date of first treatment with Y90 microspheres. Kaplan-Meier survival curves and analysis (log-rank test) were used to assess differences in survival among our sample based on the underlying cause of HCC.
Results
105 patients with HCC (76 males, 29 females, median age: 71 years, range: 33-93 years) were included. The underlying liver disease included hepatitis B (n=6; 5.7%), hepatitis C (n=28; 26.7%), alcoholic cirrhosis (n=17; 16.2%), hemochromatosis (n=4; 3.8%), cryptogenic cirrhosis (n=38; 36.2%), and multiple etiologies including hepatitis B, hepatitis C, and/or alcohol cirrhosis (n=12; 11.4%). Median overall survival was 330 days (range: 2-1287 days): hepatitis B, 317 days; hepatitis C, 172 days; alcoholic cirrhosis, 240 days; hemochromatosis, 219 days; cryptogenic cirrhosis, 325 days; or cirrhosis of multiple etiologies, 224 days. The survival distributions did not vary significantly by underlying HCC diagnosis based on the log-rank test (p=0.150). Of the patients with cryptogenic cirrhosis, 84.2% (n=32) had ≥1 risk factor for nonalcoholic fatty liver disease.
Conclusions
In this single-center retrospective review, overall survival of HCC patients treated with Y90 microspheres does not significantly differ by underlying HCC etiology. Further study is needed to determine if the differences observed, such as longer survival for hepatitis B relative to hepatitis C, trend towards significance.